Accordingly, identifying and targeting rewired energy metabolism is a relevant strategy for developing non-ABL-related therapeutic options for treating TKI-resistant CML patients, preventing the appearance of TKI-resistant cells, and LSC persistence. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.